MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on February 27, 2007; DOI: 10.1124/mol.106.033118

0026-895X/07/7106-1445-1456$20.00
Mol Pharmacol 71:1445-1456, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.033118v1
71/6/1445    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bifulco, M.
Right arrow Articles by Santoro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bifulco, M.
Right arrow Articles by Santoro, A.
Minireview

Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects

Maurizio Bifulco, Claudia Grimaldi, Patrizia Gazzerro, Simona Pisanti, and Antonietta Santoro

Department of Pharmaceutical Sciences, University of Salerno, Fisciano (Salerno), Italy

The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the ability of the clinicians to manage obesity. Large-scale clinical trials have demonstrated that rimonabant therapy can reduce obesity. Although, the precise mechanisms of action of rimonabant have to be further dissected, it is emerging, from both preclinical and clinical research, that not only is rimonabant an antiobesity drug, but also its pleiotropic functions affect a broad range of diseases, from obesity-related comorbidities to drug dependence and cancer. Here we review recent data from the literature and discuss the full pharmacological potential of this drug.

Received November 29, 2006; accepted February 27, 2007

Address correspondence to: Prof. Maurizio Bifulco, Department of Pharmaceutical Sciences, University of Salerno, Via Ponte don Melillo, 84084 Fisciano, Salerno, Italy. E-mail: maubiful{at}unisa.It




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza
Endocannabinoids in endocrine and related tumours
Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. M. Simon and B. F. Cravatt
Anandamide Biosynthesis Catalyzed by the Phosphodiesterase GDE1 and Detection of Glycerophospho-N-acyl Ethanolamine Precursors in Mouse Brain
J. Biol. Chem., April 4, 2008; 283(14): 9341 - 9349.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics